Astrazeneca (AZN) Other Operating Expenses (2009 - 2026)

Astrazeneca's Other Operating Expenses history runs 18 years deep, the most recent figure standing at $189.0 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 67.26% year-over-year to $189.0 million; the TTM figure through Mar 2026 stood at $457.0 million (up 53.36% YoY), while the FY2025 annual figure was $381.0 million, up 51.19% from the prior year.
• Other Operating Expenses was $189.0 million for Q1 2026 at Astrazeneca, up from $100.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $784.0 million in Q2 2023 to a low of $25.0 million in Q3 2024.
• Historically, Other Operating Expenses has averaged $157.4 million across 5 years, with a median of $100.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses jumped 542.62% in 2023, then plunged 92.35% in 2024.
• A 5-year view of Other Operating Expenses shows it stood at $189.0 million in 2022, then plunged by 43.39% to $107.0 million in 2023, then slipped by 6.54% to $100.0 million in 2024, then changed by 0.0% to $100.0 million in 2025, then jumped by 89.0% to $189.0 million in 2026.
• The last three Other Operating Expenses figures came in at $189.0 million (Q1 2026), $100.0 million (Q4 2025), and $89.0 million (Q3 2025), per Business Quant data.